Suppr超能文献

用巨细胞病毒载体增强活疟疾疫苗可通过先天性和适应性机制延长免疫。

Boosting Live Malaria Vaccine with Cytomegalovirus Vector Can Prolong Immunity through Innate and Adaptive Mechanisms.

作者信息

Gbedande Komi, Ibitokou Samad A, Ong Monique L, Degli-Esposti Mariapia A, Brown Michael G, Stephens Robin

机构信息

Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555-0435.

Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Cancer Center, 205 S. Orange Avenue, Newark, NJ 07103.

出版信息

bioRxiv. 2023 May 16:2023.05.02.539025. doi: 10.1101/2023.05.02.539025.

Abstract

Vaccines to persistent parasite infections have been challenging, and current iterations lack long-term protection. Cytomegalovirus (CMV) chronic vaccine vectors drive protection against SIV, tuberculosis and liver-stage malaria correlated with antigen-specific CD8 T cells with a Tem phenotype. This phenotype is likely driven by a combination of antigen-specific and innate adjuvanting effects of the vector, though these mechanisms are less well understood. Sterilizing immunity from live vaccination lasts less than 200 days. While -specific antibody levels remain stable after vaccination, the decay of parasite-specific T cells correlates with loss of challenge protection. Therefore, we enlisted murine CMV as a booster strategy to prolong T cell responses against malaria. To study induced T cell responses, we included MSP-1 epitope B5 (MCMV-B5). We found that MCMV vector alone significantly protected against a challenge infection 40-60 days later, and that MCMV-B5 was able to make B5-specific Teff, in addition to previously-reported Tem, that survive to the challenge timepoint. Used as a booster, MCMV-B5 prolonged protection from heterologous infection beyond day 200, and increased B5 TCR Tg T cell numbers, including both a highly-differentiated Tem phenotype and Teff, both previously reported to protect. B5 epitope expression was responsible for maintenance of Th1 and Tfh B5 T cells. In addition, the MCMV vector had adjuvant properties, contributing non-specifically through prolonged stimulation of IFN-γ. neutralization of IFN-γ, but not IL-12 and IL-18, late in the course of MCMV, led to loss of the adjuvant effect. Mechanistically, sustained IFN-γ from MCMV increased CD8α dendritic cell numbers, and led to increased IL-12 production upon challenge. In addition, neutralization of IFN-γ before challenge reduced the polyclonal Teff response to challenge. Our findings suggest that, as protective epitopes are defined, an MCMV vectored booster can prolong protection through the innate effects of IFN-γ.

摘要

针对持续性寄生虫感染的疫苗一直具有挑战性,目前的迭代产品缺乏长期保护作用。巨细胞病毒(CMV)慢性疫苗载体可驱动针对猴免疫缺陷病毒(SIV)、结核病和肝期疟疾的保护作用,这与具有效应记忆T细胞(Tem)表型的抗原特异性CD8 T细胞相关。这种表型可能是由载体的抗原特异性和固有佐剂效应共同驱动的,尽管这些机制尚不太清楚。来自活疫苗接种的灭菌免疫持续时间不到200天。虽然接种疫苗后特异性抗体水平保持稳定,但寄生虫特异性T细胞的衰减与攻击保护作用的丧失相关。因此,我们采用鼠巨细胞病毒作为增强策略来延长针对疟疾的T细胞反应。为了研究诱导的T细胞反应,我们纳入了疟原虫裂殖子表面蛋白1(MSP-1)表位B5(MCMV-B5)。我们发现单独的MCMV载体在40 - 60天后能显著保护机体免受攻击感染,并且MCMV-B5除了能产生先前报道的Tem外还能产生B5特异性效应T细胞(Teff),这些细胞能存活至攻击时间点。作为增强剂使用时,MCMV-B5将针对异源感染的保护作用延长至200天以上,并增加了B5 TCR转基因T细胞数量,包括高度分化的Tem表型和Teff,这两种细胞先前都被报道具有保护作用。B5表位表达负责维持Th1和滤泡辅助性T细胞(Tfh)B5 T细胞。此外,MCMV载体具有佐剂特性,通过延长对干扰素-γ(IFN-γ)的刺激产生非特异性作用。在MCMV病程后期中和IFN-γ,但不中和白细胞介素-12(IL-12)和白细胞介素-18,会导致佐剂效应丧失。从机制上讲,MCMV持续产生的IFN-γ增加了CD8α树突状细胞数量,并导致攻击时IL-12产生增加。此外,如果在攻击前中和IFN-γ,则会降低对攻击的多克隆Teff反应。我们的研究结果表明,随着保护性表位的确定,一种MCMV载体增强剂可通过IFN-γ的固有作用延长保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43da/10201634/4400bf0ea366/nihpp-2023.05.02.539025v2-f0001.jpg

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验